GLP-1 Access Is EXPLODING… But Something Else Is Happening

GLP-1 Access Is EXPLODING… But Something Else Is Happening

If you just look at the headlines, things look great for access to GLP-1 medications but for some of those already using these medications things are changing and getting tighter. Listen in as Dave breaks down the news of the week and puts it all in context.


Topics:

The GLP-1 paradox, Rise of telehealth powerhouses, FDA guidance on compounding, Enforcement risks and industry impact, Peptide imports and gray market concerns, New branded drug developments, Expansion of oral GLP-1 medications, New oral drug launches, Where the market is heading.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(197)

How To Get $50 GLP-1

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...

23 Jun 44min

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ​⁠ to break down the molecules, clinica...

16 Jun 1h 15min

Retatrutide Just Reached Bariatric Surgery Results

Retatrutide Just Reached Bariatric Surgery Results

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference....

11 Jun 48min

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

9 Jun 20min

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Jun 20min

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

https://linktr.ee/manonthemounjaro

26 Mai 30min

Lilly Bets $8B on Weight Loss Future

Lilly Bets $8B on Weight Loss Future

https://linktr.ee/manonthemounjaro

19 Mai 23min

The Next Two Weeks in GLP1 Are Huge, Here's Why

The Next Two Weeks in GLP1 Are Huge, Here's Why

http://www.otplinks.com

12 Mai 1h 7min

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
hvordan-har-du-det-mann
leger-om-livet
psykodrama
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-skravla-gar
foreldreradet
rss-garne-damer
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
morten-ramm-lar-kakla-ga-til-du-sovner
g-punktet
rss-kunsten-a-leve
klimaks
hjernesterk
aftenbladet-intervjuer
treningsprat
kjed-deg-i-sovn-verdens-kjedeligste-podcast
biohacking-girls-din-podcast-for-optimal-helse